<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538599</url>
  </required_header>
  <id_info>
    <org_study_id>BHCT-RD13-01-02</org_study_id>
    <nct_id>NCT04538599</nct_id>
  </id_info>
  <brief_title>RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies</brief_title>
  <official_title>RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>He Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed&#xD;
      and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and&#xD;
      pharmacokinetics of RD13-01 in patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>4 weeks after infusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>RD13-01 cell infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RD13-01 cell infusion</intervention_name>
    <description>Universal CAR-T cells targeting CD7</description>
    <arm_group_label>RD13-01 cell infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 3 to 70 years.&#xD;
&#xD;
          2. Diagnosis of r/r T-ALL/NK-ALL, T-LBL, or T-NHL (including PTCL-NOS, AITL, ALCL,&#xD;
             Extranodal NK/T cell lymphoma).&#xD;
&#xD;
          3. ECOG: 0-2.&#xD;
&#xD;
          4. Life expectancy greater than 12 weeks.&#xD;
&#xD;
          5. Cardiac left ventricle ejection fraction ≥50%.&#xD;
&#xD;
          6. Informed consent explained to, understood by and signed by the patient/guardian.&#xD;
             Patient/guardian is given a copy of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating.&#xD;
&#xD;
          2. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and&#xD;
             peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal&#xD;
             range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C&#xD;
             Viral (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive;&#xD;
             cytomegalovirus (CMV) DNA positive; syphilis positive.&#xD;
&#xD;
          3. Patients with graft-versus-host disease (GVHD) or who need to use immunosuppressive&#xD;
             drugs.&#xD;
&#xD;
          4. Participated in other clinical studies within 2 weeks prior to screening.&#xD;
&#xD;
          5. History of alcoholism, drug abuse or mental illness.&#xD;
&#xD;
          6. Any situations that the investigator believes may increase the risk of patients or&#xD;
             interfere with the results of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital，College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, PhD</last_name>
      <phone>86-13605714822</phone>
      <email>hehuangyu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 30, 2020</last_update_submitted>
  <last_update_submitted_qc>August 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

